UNII 3OWL53L36A

MANNITOL

Unique Ingredient Identifier 3OWL53L36A is listed as a ingredient substance
RN69-65-8
EC200-711-8
NCITC625
RXCUI6628
MFC6H14O6
INCHI KEYFBPFZTCFMRRESA-KVTDHHQDSA-N
SMILESOC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

Alternate Names

Dosage Forms

UNII 3OWL53L36A MANNITOL is commonly included in medications in the following forms.

RouteDosage FormPotency
BUCCALGUM, CHEWING37.11 MG
BUCCALTABLET97.69 MG
BUCCAL/SUBLINGUALTABLET52.5 MG
IM - IVINJECTION2.5 %
IM - IVPOWDER, FOR INJECTION SOLUTION30 %
IM - IV - SCINJECTION NA
IM - SCINJECTION NA
IM - SCPOWDER, FOR INJECTION SOLUTION2 %
INJECTIONINJECTABLE125 MG/VIAL
INTRAMUSCULARINJECTABLE42.5 mg
INTRAMUSCULARINJECTABLE5 %
INTRAMUSCULARINJECTION88.4 mg
INTRAMUSCULARINJECTION10.66 %
INTRAMUSCULARINJECTION, MICROSPHERES13.49 %
INTRAMUSCULARPOWDER, FOR INJECTION SOLUTION11.93 %
INTRAMUSCULARPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED8.5 %
INTRAMUSCULARPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED, WITH 3.6 %
INTRAMUSCULARPOWDER, FOR INJECTION SUSPENSION4.5 %W/V
INTRAMUSCULARPOWDER, FOR INJECTION SUSPENSION, LYOPHILIZED5.19 %
INTRAVENOUSINFUSION17 %
INTRAVENOUSINJECTABLE125 MG/1VIAL
INTRAVENOUSINJECTABLE45 %
INTRAVENOUSINJECTABLE41.5 MG/1ML
INTRAVENOUSINJECTION4950 MG/100ML
INTRAVENOUSINJECTION100 mg/1VIAL
INTRAVENOUSINJECTION33.9 %
INTRAVENOUSINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION100 MG/1VIAL
INTRAVENOUSINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION4.8 %
INTRAVENOUSINJECTION, SUSPENSION2.5 %
INTRAVENOUSLIQUID4.1 %
INTRAVENOUSLIQUID, CONCENTRATE, INJECTION6.13 %
INTRAVENOUSPOWDER45 %
INTRAVENOUSPOWDER FOR INJECTION DOSAGE FORM150 mg/1VIAL
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION125 mg/1VIAL
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION38 MG/1ML
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION34 %
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED80 MG/1VIAL
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED36 mg/vial
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED, WITH 3.94 %
INTRAVENOUSSOLUTION4.15 %
INTRAVENOUSSOLUTION, INJECTION6.25 %
INTRAVENOUSSOLUTION, LIPOSOME, INJECTION10 %
INTRAVENOUS INFUSIONINJECTABLE125 MG/VIAL
INTRAVENOUS INFUSIONINJECTION51 mg/1mL
INTRAVENOUS INFUSIONINJECTION5.1 %
IV(INFUSION)CONCENTRATE22 %
IV(INFUSION)INFUSION3.85 %
IV(INFUSION)INJECTABLE4.4 %
IV(INFUSION)INJECTION4950 MG/100ML
IV(INFUSION)INJECTION51 mg/1mL
IV(INFUSION)INJECTION47 %
IV(INFUSION)POWDER, FOR INJECTION SOLUTION75 %
IV(INFUSION)POWDER, FOR INJECTION SOLUTION, LYOPHILIZED42.5 MG/1VIAL
IV(INFUSION)POWDER, FOR INJECTION SOLUTION, LYOPHILIZED4 %
IV(INFUSION)POWDER, FOR INJECTION SOLUTION, LYOPHILIZED, WITH 7.5 %
IV(INFUSION)SOLUTION3.85 %
IV(INFUSION)SOLUTION, CONCENTRATE4.4 %
IV(INFUSION)SOLUTION, INJECTION20.67 %
NASALSOLUTION, SPRAY4.15 %
OPHTHALMICGEL5 %
OPHTHALMICPOWDER, FOR SOLUTION5.6 %
OPHTHALMICSOLUTION47 MG/1ML
OPHTHALMICSOLUTION23 %
OPHTHALMICSOLUTION, DROPS16 mg/1mL
OPHTHALMICSOLUTION, DROPS4.6 %
OPHTHALMICSOLUTION, GEL FORMING, EXTENDED RELEASE4.35 %
OPHTHALMICSUSPENSION2.4 %
OPHTHALMICSUSPENSION, DROPS4 %
ORALCAPSULE297.2 MG
ORALCAPSULE (IMMED./COMP. RELEASE), HARD GELATIN264.8 MG
ORALCAPSULE, COATED PELLETS1.75 MG
ORALCAPSULE, DELAYED ACTION227 MG
ORALCAPSULE, DELAYED ACTION, ENTERIC COATED NA
ORALCAPSULE, DELAYED RELEASE39.1 MG
ORALCAPSULE, ENTERIC COATED PELLETS236 MG
ORALCAPSULE, EXTENDED RELEASE6.42 MG
ORALCAPSULE, HARD GELATIN92 MG
ORALCAPSULE, SUSTAINED ACTION56.1 MG
ORALDISPERSIBLE TABLET58.3 MG
ORALGRANULE487.09 mg
ORALGRANULE, EFFERVESCENT NA
ORALGRANULE, FOR ORAL SUSPENSION193.2 MG
ORALGRANULE, FOR SUSPENSION500 MG
ORALLOZENGE972 mg
ORALPOWDER1100 MG/1PKT
ORALPOWDER1100 MG/1SCP
ORALPOWDER, FOR ORAL SOLUTION755 MG
ORALPOWDER, FOR ORAL SUSPENSION1196.75 MG
ORALPOWDER, FOR RECONSTITUTION293.62 MG/5ML
ORALPOWDER, FOR SOLUTION45.86 MG/1ML
ORALPOWDER, FOR SUSPENSION421.92 g
ORALPOWDER, FOR SUSPENSION200 MG/5ML
ORALPOWDER, FOR SUSPENSION0.339 g/236mL
ORALSOLUTION747 MG
ORALSOLUTION, INJECTION50 MG/1.7ML
ORALSUSPENSION500 MG/5ML
ORALSUSPENSION, SUSTAINED ACTION2464.6 MG/1PKT
ORALTABLET681.65 MG
ORALTABLET (IMMED./COMP. RELEASE), FILM COATED181.5 MG
ORALTABLET (IMMED./COMP. RELEASE), UNCOATED, CHEWABLE630 MG
ORALTABLET, CHEWABLE410.6 MG
ORALTABLET, COATED177.7 MG
ORALTABLET, CONTROLLED RELEASE NA
ORALTABLET, DELAYED ACTION110.08 MG
ORALTABLET, DELAYED ACTION, ENTERIC COATED77.9 MG
ORALTABLET, DELAYED RELEASE213 MG
ORALTABLET, DISPERSIBLE104 MG
ORALTABLET, EXTENDED RELEASE384.75 MG
ORALTABLET, FILM COATED241.21 MG
ORALTABLET, FOR SUSPENSION270 MG
ORALTABLET, ORALLY DISINTEGRATING606.72 MG
ORALTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE261.33 mg
ORALTABLET, SUSTAINED ACTION392.2 MG
ORALTABLET, SUSTAINED ACTION, FILM COATED274.97 MG
ORALTABLET, UNCOATED, LOZENGE187.6 MG
ORALTROCHE1035.18 MG
ORALWAFER500 MG
PARENTERALINJECTION4.4 %
PARENTERALPOWDER, FOR INJECTION SOLUTION20 %
RESPIRATORY (INHALATION)POWDER, FOR INHALATION0.051 %
SUBCUTANEOUSINJECTABLE40 MG/1ML
SUBCUTANEOUSINJECTABLE10 %
SUBCUTANEOUSINJECTION100 mg/1VIAL
SUBCUTANEOUSINJECTION40 MG/1ML
SUBCUTANEOUSINJECTION10 %
SUBCUTANEOUSINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION100 MG/1VIAL
SUBCUTANEOUSPOWDER, FOR INJECTION SOLUTION9 %
SUBCUTANEOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED22.05 %
SUBCUTANEOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED, WITH 4 %
SUBCUTANEOUSPOWDER, FOR INJECTION SUSPENSION, LYOPHILIZED10 %
SUBCUTANEOUSSOLUTION1.59 %
SUBCUTANEOUSSOLUTION, INJECTION4.95 %
SUBCUTANEOUSSUSPENSION, INJECTION1.21 %
SUBLINGUALTABLET204 MG
SUBLINGUALTABLET (IMMED./COMP. RELEASE), UNCOATED, BUCCAL157.48 MG
SUBLINGUALTABLET, ORALLY DISINTEGRATING10.25 mg
SUBMUCOSALSOLUTION, INJECTION2.94 %
TOPICALSOLUTION2.39 %W/V
TOPICALSOLUTION, DROPS1.6 %W/V
TOPICALSUSPENSION0.3 %W/W
TOPICALSUSPENSION, DROPS1.01 %W/W
TRANSDERMALPATCH, ELECTRICALLY CONTROLLED342.35 MG
TRANSMUCOSALTABLET180.19 MG
ORALCAPSULE336.6 mg
ORALCAPSULE266.7 mg
ORALCAPSULE258 mg
ORALTABLET97.93 mg
ORALTABLET35.45 mg

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.